Boyds

Conversations in Drug Development

Science EN ↓ Odcinki: 28

Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: conversationsindrugdevelopmentwithboyds.podbean.com

Autor

Boyds

Kategoria

Science

Strona podcastu

conversationsindrugdevelopmentwithboyds.podbean.com

Ostatni odcinek

13 paź 2026

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Zainstaluj za darmo Android prawie 10 mln pobrań · ocena 4,8 iOS niedługo

Odcinki

Off-the-Shelf Cell Therapies: Breaking Barriers and Revolutionizing Patient Care 04.12.2023 20:30

In this episode of "Conversations in Drug Development", Harriet Edwards and Dr. Patrick Ginty discuss off-the-shelf cell therapies, explaining how these therapies are manufactured and their ability to treat multiple recipients. While these therapies offer scalability and the potential to treat larger patient populations, they also carry risks such as immune reactions. Dr. Ginty highlights the impo...

The Future of Drug Development: AI’s Role in Revolutionizing the Industry 08.11.2023 22:13

In this episode of Conversations in Drug Development, Dr. Julie Warner and Harriet Edwards discuss the revolutionizing role of artificial intelligence (AI) in drug development, exploring its applications in data analysis and toxicity prediction, and its potential to reduce animal testing. Join us in this conversation, as we discuss the challenges of regulating AI in this rapidly evolving field and...

Recent Trends in Oncology Drug Development 04.10.2023 25:14

In this episode, Dr Katherine Bowen and Dr Julie Warner delve deep into the ever-evolving world of oncology drug development and the regulatory landscape in the US and EU. Join us in this conversation, as we cover the key shifts in the field over the past few decades, regulatory challenges, FDA initiatives and future developments in oncology drug development, including the impact of AI, machine le...